Assessment of uS17 Expression in Colorectal Cancer Cell Lines HT-29 and HCT116 Reveals Minimal Variation
DOI:
https://doi.org/10.33736/tur.7957.2025Keywords:
Colorectal cancer, Gene expression, ribosomal protein, uS17Abstract
Colorectal cancer (CRC) is a malignant neoplasm that develops in the large intestine, specifically in the colon and rectum. The ribosomal protein gene uS17 (RPS11) has been found to be overexpressed in CRC tissues, while its presence in normal colorectal mucosa is minimal. However, its expression pattern across different types of CRC remains poorly understood and its prognostic potentials is underexplored. In this study, we investigated the expression levels of uS17 in two CRC cell lines, HT29 and HCT116, to assess potential differences in expression between these cell types. HT29 was derived from a late-stage primary colorectal adenocarcinoma, whereas HCT116 originated from an advanced-stage metastatic colorectal carcinoma. A semi-quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay, along with a two-tailed unpaired t-test for inferential statistical analysis, were used in our evaluation. Although a higher uS17 expression level was observed in the HT29 cell line compared to HCT116, the difference was not statistically significant, suggesting minimal variation in uS17 expression between two different CRC cell lines of different origins, cellular differentiation, and stages of malignancy. While further studies incorporating additional cell lines and in situ tissue analyses are warranted, our findings offer novel insights into the expression profile of uS17 in specific CRC cell models.
References
Advani, S. M., Swartz, M. D., Loree, J., Davis, J. S., Sarsashek, A. M., Lam, M., Lee, M. S., Bressler, J., Lopez, D. S., Daniel, C. R., Morris, V., Shureqi, I., Kee, B., Dasari, A., Vilar, E., Overman, M., Hamilton, S., Maru, D., Braithwaite, D., & Kopetz, S. (2021). Epidemiology and molecular-pathologic characteristics of CpG Island methylator phenotype (CIMP) in colorectal cancer. Clinical Colorectal Cancer, 20(2), 137-147. https://doi.org/10.1016/j.clcc.2020.09.007
Ahmed, D., Eide, P. W., Eilertsen, I. A., Danielsen, S. A., Eknaes, M., Hektoen, M., Lind, G. E., & Lothe, R. A. (2013). Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis, 2(9), e71. https://doi.org/10.1038/oncsis.2013.35
Alam, E., Maaliki, L., & Nasr, Z. (2020). Ribosomal protein S3 selectively affects colon cancer growth by modulating the levels of p53 and lactate dehydrogenase. Molecular Biology Reports, 47(8), 6083-6090. https://doi.org/10.1007/s11033-020-05683-1
Djursby, M., Madsen, M. B., Frederiksen, J. H., Berchtold, L. A., Therkildsen, C., Willemoe, G. L., Hasselby, J. P., Wikman, F., Okkels, H., Skytte, A. B., Nilbert, M., Wadt, K., Gerdes, A. M., & van Overeem Hansen, T. (2020). New pathogenic germline variants in very early onset and familial colorectal cancer patients. Frontiers in Genetics, 11, 566266. doi: 10.3389/fgene.2020.566266
El Khoury, W., & Nasr, Z. (2021). Deregulation of ribosomal proteins in human cancers. Bioscience Reports, 41(12), BSR20211577. https://doi.org/10.1042/BSR20211577
Grothey, A., Fakih, M., & Tabernero, J. (2021). Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Annals of Oncology, 32(8), 959-967. https://doi.org/10.1016/j.annonc.2021.03.206
Jørgensen, K. H., et al. (1982). "Cell kinetics of a human colonic carcinoma cell line (HT-29) in nude mice." Virchows Archiv B, 40(3), 297-307. doi:10.1007/BF02899711.
Kasai, H., Nadano, D., Hidaka, E., Higuchi, K., Kawakubo, M., Sato, T. A., & Nakayama, J. (2003). Differential expression of ribosomal proteins in human normal and neoplastic colorectum. Journal of Histochemistry & Cytochemistry, 51(5), 567-573. https://doi.org/10.1177/002215540305100502
Le Bivic, A., Hirn, M., & Reggio, H. (1988). HT-29 cells are an in vitro model for the generation of cell polarity in epithelia during embryonic differentiation. Proceedings of the National Academy of Sciences, 85(1), 136-140. https://doi.org/10.1073/pnas.85.1.136
Leibovitz, A., Stinson, J. C., McCombs III, W. B., McCoy, C. E., Mazur, K. C., & Mabry, N. D. (1976). Classification of human colorectal adenocarcinoma cell lines. Cancer Research, 36(12), 4562-4569. ISSN 1538-7445
Liebl, M. C., & Hofmann, T. G. (2021). The role of p53 signaling in colorectal cancer. Cancers, 13(9), 2125. https://doi.org/10.3390/cancers13092125
Mao-De, L., & Jing, X. (2007). Ribosomal proteins and colorectal cancer. Current genomics, 8(1), 43-49. https://doi.org/10.2174/138920207780076938
Markowitz, S. D., & Bertagnolli, M. M. (2009). Molecular origins of cancer: Molecular basis of colorectal cancer. New England Journal of Medicine, 361(25), 2449-2460. https://doi.org/10.2174/138920207780076938
Meng, M., Zhong, K., Jiang, T., Liu, Z., Kwan, H. Y., & Su, T. (2021). The current understanding on the impact of KRAS on colorectal cancer. Biomedicine & Pharmacotherapy, 140, 111717. https://doi.org/10.1016/j.biopha.2021.111717
Michel, M., Kaps, L., Maderer, A., Galle, P. R., & Moehler, M. (2021). The role of p53 dysfunction in colorectal cancer and its implication for therapy. Cancers, 13(10), 2296. https://doi.org/10.3390/cancers13102296
Mittal, V. K., Bhullar, J. S., & Jayant, K. (2015). Animal models of human colorectal cancer: Current status, uses and limitations. World Journal of Gastroenterology, 21(41), 11854. https://doi.org/10.3748/wjg.v21.i41.11854
Molina-Cerrillo, J., San Román, M., Pozas, J., Alonso-Gordoa, T., Pozas, M., Conde, E., Rosas, M., Grande, E., García-Bermejo, M. L., & Carrato, A. (2020). BRAF mutated colorectal cancer: new treatment approaches. Cancers, 12(6), 1571. https://doi.org/10.3390/cancers12061571
Mouradov, D., Sloggett, C., Jorissen, R. N., Love, C. G., Li, S., Burgess, A. W., Arango, D., Strausberg, R. L., Buchanan, D., Wormald, S., O'Connor, L., Wilding, J. L., Bicknell, D., Tomlinson, I. P., Bodmer, W. F., Mariadason, J. M., & Sieber, O. M. (2014). Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Research, 74(12), 3238-3247. https://doi.org/10.1158/0008-5472.CAN-14-0013
Nieminen, T. T., O’Donohue, M. F., Wu, Y., Lohi, H., Scherer, S. W., Paterson, A. D., Ellonen, P., Abdel-Rahman, W. M., Valo, S., Mecklin, J. P., Järvinen, H. J., Gleizes, P. E., & Peltomäki, P. (2014). Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary nonpolyposis colorectal carcinoma without DNA mismatch repair deficiency. Gastroenterology, 147(3), 595-598. https://doi.org/10.1053/j.gastro.2014.06.009
Olkinuora, A. P., Peltomäki, P. T., Aaltonen, L. A., & Rajamäki, K. (2021). From APC to the genetics of hereditary and familial colon cancer syndromes. Human Molecular Genetics, 30(R2), R206-R224. https://doi.org/10.1093/hmg/ddab208
Sim, E.U.H., Mutsamy, S., & Teh, Z.Y. (2020). Expression patterns of the human ribosomal protein genes, eL14 and uS19 in colon cancer is dependent on the type and stage of the cancer cell. Malaysian Applied Biology Journal, 49 (1), 31-39. https://doi.org/10.55230/mabjournal.v49i1.1652
Tian, Y., Babaylova, E. S., Gopanenko, A. V., Tupikin, A. E., Kabilov, M. R., Malygin, A. A., & Karpova, G. G. (2022). Changes in the transcriptome caused by mutations in the ribosomal protein uS10 associated with a predisposition to colorectal cancer. International Journal of Molecular Sciences, 23(11), 6174. https://doi.org/10.3390/ijms23116174
Wang, J., Deng, Z., Lang, X., Jiang, J., Xie, K., Lu, S., Hu, Q., Huo, Y., Xiong, X., Zhu, N., & Zhang, W. (2022). Meta‐Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer. Disease Markers, 2022(1), 4254862. https://doi.org/10.1155/2022/4254862
Van Erk, M. J., Krul, C. A. M., Caldenhoven, E., Stierum, R. H., Peters, W. H., Woutersen, R. A., & Van Ommen, B. (2005). Expression profiling of colon cancer cell lines and colon biopsies: towards a screening system for potential cancer-preventive compounds. European Journal of Cancer Prevention, 14(5), 439-457. 10.1097/01.cej.0000174781.51883.21
Yamamoto, H., Watanabe, Y., Maehata, T., Imai, K., & Itoh, F. (2020). Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach. Archives of toxicology, 94, 3349-3357. https://doi.org/10.1007/s00204-020-02833-z
Yi, Y. W., You, K. S., Park, J. S., Lee, S. G., & Seong, Y. S. (2021). Ribosomal protein S6: a potential therapeutic target against cancer? International Journal of Molecular Sciences, 23(1), 48. https://doi.org/10.3390/ijms23010048
Yong, W. H., Shabihkhani, M., Telesca, D., Yang, S., Tso, J. L., Menjivar, J. C., Wei, B., Lucey, G. M., Mareninov, S., Chen, Z., Liau, L. M., Lai, A., Nelson, S. F., Cloughesy, T. F., & Tso, C. L. (2015). Ribosomal proteins RPS11 and RPS20, two stress-response markers of glioblastoma stem cells, are novel predictors of poor prognosis in glioblastoma patients. PLoS One, 10(10), e0141334. doi: 10.1371/journal.pone.0141334.
Zhou, C., Sun, J., Zheng, Z., Weng, J., Atyah, M., Zhou, Q., Chen, W., Zhang, Y., Huang, J., Yin, Y., Mao, H., Zhang, Z., Yi, Y., & Ren, N. (2020). High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection. Annals of Translational Medicine, 8(7), 466. doi: 10.21037/atm.2020.03.92.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 UNIMAS Publisher
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright Transfer Statement for Journal
1) In signing this statement, the author(s) grant UNIMAS Publisher an exclusive license to publish their original research papers. The author(s) also grant UNIMAS Publisher permission to reproduce, recreate, translate, extract or summarize, and to distribute and display in any forms, formats, and media. The author(s) can reuse their papers in their future printed work without first requiring permission from UNIMAS Publisher, provided that the author(s) acknowledge and reference publication in the Journal.
2) For open access articles, the author(s) agree that their articles published under UNIMAS Publisher are distributed under the terms of the CC-BY-NC-SA (Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License) which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original work of the author(s) is properly cited.
3) For subscription articles, the author(s) agree that UNIMAS Publisher holds copyright, or an exclusive license to publish. Readers or users may view, download, print, and copy the content, for academic purposes, subject to the following conditions of use: (a) any reuse of materials is subject to permission from UNIMAS Publisher; (b) archived materials may only be used for academic research; (c) archived materials may not be used for commercial purposes, which include but not limited to monetary compensation by means of sale, resale, license, transfer of copyright, loan, etc.; and (d) archived materials may not be re-published in any part, either in print or online.
4) The author(s) is/are responsible to ensure his or her or their submitted work is original and does not infringe any existing copyright, trademark, patent, statutory right, or propriety right of others. Corresponding author(s) has (have) obtained permission from all co-authors prior to submission to the journal. Upon submission of the manuscript, the author(s) agree that no similar work has been or will be submitted or published elsewhere in any language. If submitted manuscript includes materials from others, the authors have obtained the permission from the copyright owners.
5) In signing this statement, the author(s) declare(s) that the researches in which they have conducted are in compliance with the current laws of the respective country and UNIMAS Journal Publication Ethics Policy. Any experimentation or research involving human or the use of animal samples must obtain approval from Human or Animal Ethics Committee in their respective institutions. The author(s) agree and understand that UNIMAS Publisher is not responsible for any compensational claims or failure caused by the author(s) in fulfilling the above-mentioned requirements. The author(s) must accept the responsibility for releasing their materials upon request by Chief Editor or UNIMAS Publisher.
6) The author(s) should have participated sufficiently in the work and ensured the appropriateness of the content of the article. The author(s) should also agree that he or she has no commercial attachments (e.g. patent or license arrangement, equity interest, consultancies, etc.) that might pose any conflict of interest with the submitted manuscript. The author(s) also agree to make any relevant materials and data available upon request by the editor or UNIMAS Publisher.
